InVivo Therapeutics Hldgs Corp (fka NVIVQ)

[BioBull1]

Investors may once again face additional dilution unless something drastically changes. The company had 41M as of June 2016 at a burn rate of ~1.5M per month. At the end of the year, Invivo will have roughly 33M. If we are currently burning through one and half million dollars a month supporting just one trial (how?), I anticipate an increase if Cervical SCI and Chronic trials ever take off. Therefore, for calendar year 2017, I am assuming Invivo now burns 2.1M per month (potentially more) or a little over 25 million. If the HDE is not submitted until Q1 or 1H of 2018, Invivo will be running on fumes once again with less than 10M in the bank. This is not accounting for any further delays, ongoing or new lawsuits, additional hires, etc.